Theriva Biologics (TOVX) Q2 2026 earnings summary

Executive summary

• Focused on oncology therapeutics, especially VCN-01 for pancreatic cancer, retinoblastoma, and HNSCC, following the acquisition of VCN Biosciences.

• Achieved positive FDA feedback for Phase 3 trial design of VCN-01 in metastatic PDAC; initiated and dosed first patients in the VIRAGE2 Phase 2a trial for more frequent dosing.

• Out-licensed SYN-020 to Rasayana Therapeutics, receiving a $300,000 upfront payment and potential milestones/royalties.

• Clinical progress in VCN-01 programs for PDAC, retinoblastoma, and HNSCC, with new trial designs and published Phase 1 results.

Financial highlights

• Revenue for the six months ended June 30, 2026 was $300,000, from the SYN-020 license agreement.

• Net loss for the six months ended June 30, 2026 was $5.3 million, a significant improvement from $17.4 million in the prior year period; Q2 net loss was $3.2 million, down from $13.1 million year-over-year.

• Cash and cash equivalents were $11.3 million as of June 30, 2026, down from $13.1 million at year-end 2025.

• Operating expenses, including R&D and G&A, decreased sharply year-over-year, with G&A down 82% to $2.0 million and R&D down 35% to $1.3 million.

Outlook and guidance

• Current cash is expected to fund operations into Q1 2027, covering only limited clinical, regulatory, and preclinical activities.

• Additional capital will be required for larger Phase 3 trials and further development; management is actively pursuing financing and strategic alternatives.

• VIRAGE2 trial enrollment expected to complete in H2 2026, with initial data anticipated by Q3 2027.

• Plans to discuss the proposed Phase 2/3 retinoblastoma trial protocol with the FDA in Q3 2026.

• No assurance of sufficient funding; failure to secure capital may force delays or cessation of development programs.